SCHEMBL7318366

SCHEMBL7318366

NCCc1cn(Cc2ccc(C(=O)O)s2)c2ccc(OCc3ccc(F)cc3Cl)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.45
IGF1R P08069 6/20 0.45
FLT4 P35916 6/20 0.45
KDR P35968 6/20 0.45
PPARD Q03181 3/20 0.44
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ADAMTS4 O75173 1/20 0.37
MMP2 P08253 1/20 0.37
MMP13 P45452 1/20 0.37
MMP14 P50281 1/20 0.37
ADAMTS5 Q9UNA0 1/20 0.37
AKR1A1 P14550 1/20 0.37
AKR1B1 P15121 1/20 0.37
PLA2G2A P14555 3/20 0.37
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7341464 0.86 EGFR (0.44) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7310388 0.85 EGFR (0.51) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7307435 0.84 EGFR (0.47) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7314794 0.82 PPARD (0.49) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7312477 0.82 EGFR (0.52) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7319796 0.81 EGFR (0.42) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7309613 0.81 EGFR (0.41) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7320099 0.79 EGFR (0.47) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7317397 0.78 EGFR (0.54) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7313126 0.77 EGFR (0.46) EGFRIGF1RFLT4KDRPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US claimed
WO-2001034146-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2001-05-17 WO claimed
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US disclosed
WO-2001034146-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010007877-A1 NOVEL ANTI-INFECTIVES CTSL, MMP8, SERPINB1 EGFR 4683/4885IGF1R 4834/4885FLT4 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.